levomilnacipran
Also known as F-2695, Fetzima®, (1S,2R)-milnacipran, (1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Levomilnacipran, sold under the brand name Fetzima, is an antidepressant, used for the treatment of major depressive disorder in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 451552762
- Drug.image
- Levomilnacipran.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- Levomilnacipran ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Fetzima
- Drug.MedlinePlus
- a613048
- Drug.DailyMedID
- Levomilnacipran
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
~4 min read
Article
9 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- Research
- References
- External links
Levomilnacipran, sold under the brand name Fetzima, is an antidepressant, used for the treatment of major depressive disorder in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor.
Levomilnacipran was approved for medical use in the United States in July 2013.
Connections
Categories
Alzheimer's diseaseAminomethyl compoundsCarboxamidesChemical articles with multiple CAS registry numbersChemicals using indexlabelsCyclopropanesDiethylamino compoundsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by AbbVieDrugs with non-standard legal statusEnantiopure drugs